GANX Gain Therapeutics, Inc.
Healthcare$1.82+2.25%ClosedMarket Cap: $77.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
5.37
P/S
0.00
EV/EBITDA
-3.05
DCF Value
$0.61
FCF Yield
-25.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-201.4%
ROA
-113.3%
ROIC
-131.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-5.4M | $-5.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-4.5M | $-4.5M | $— | — |
| FY null | $0.00 | NaN% | $-18.7M | $-20.2M | $— | — |
| Q3 null | $0.00 | NaN% | $-4.8M | $-5.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-5.1M | $-5.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-4.4M | $-4.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-3.3M | $-3.8M | $— | — |
| FY null | $0.00 | NaN% | $-20.4M | $-20.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-4.5M | $-4.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-8.2M | $-8.1M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-4.4M | $-4.0M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-4.4M | $-4.7M | $-0.29 | — |